Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imagion Biosystems Ltd. ( (AU:IBX) ) has issued an announcement.
Imagion Biosystems has adjusted its funding structure under an existing Convertible Securities Agreement, which provides up to $15 million from U.S.-based investors Mercer Street Global Opportunity Fund and affiliated C/M Capital Partners. The company has progressively issued several tranches of convertible notes since 2023 and is now issuing a further 330,000 CMF Convertible Notes, with a face value of $1 each, from its existing placement capacity.
Under a fourth variation to the agreement, Imagion has reset floor prices for different note series and extended or clarified maturity dates, tailoring conversion terms across earlier and new tranches. A deed of novation transfers Mercer’s rights and obligations for the new CMF notes to C/M Capital Master Fund, refining counterparty responsibilities and securing an additional $300,000 in short-term funding to support the company’s ongoing operations and capital needs.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is an ASX-listed medical technology company focused on developing diagnostic imaging solutions using proprietary nanoparticle-based technologies. The company targets oncology and related clinical applications, aiming to improve cancer detection and monitoring through advanced imaging modalities for global healthcare markets.
Average Trading Volume: 1,744,631
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.3M
Find detailed analytics on IBX stock on TipRanks’ Stock Analysis page.